image description

Ms. Smith has served as Raptor’s President and CEO since January 2015 in addition to being a member of the Board of Directors. She joined the company in 2012 as Executive Vice President, Strategy and Chief Operating Officer. Prior to joining Raptor, Ms. Smith was Chief Commercial Officer of Enobia Pharma, Inc., a private, clinical stage orphan company acquired by Alexion (ALXN). Previously, she served as Vice President, Commercial where she managed commercial functions at Jazz Pharmaceuticals and as Vice President, Global Marketing at Genzyme General where she led the worldwide commercialization and planning for Myozyme, an infused enzyme replacement therapy for an ultra-orphan genetic disease. In her nearly 20 years in biotech, Ms. Smith has served in executive management of both private and public biotech firms, primarily on orphan drug development and commercial stage programs. She serves on the board of the Health and Emerging Companies Sections of the Biotechnology Industry Organization. She received a B.S. in Biological and Nutritional Science from Cornell University.

image description

Todd C. Zankel, Ph.D. co-founded Raptor and serves as our Chief Scientific Officer. From 1997 to 2005, Dr. Zankel served as a Senior Director of Research at BioMarin Pharmaceutical Inc., where he conceived and led the development of BioMarin’s protein delivery and targeting technology, including receptor associated protein (RAP). Dr. Zankel was an NIH postdoctoral fellow at both the Plant Gene Expression Center in Berkeley, California, and the Swiss Institute of Technology in Zurich, Switzerland. Dr. Zankel has authored a number of peer-reviewed articles covering various scientific areas. He earned a B.A. in Chemistry from Reed College in Portland, Oregon, and a Ph.D. in Chemistry from Columbia University, New York.

 

image description

Mr. Happel joined Raptor in October 2014 as Chief Commercial Officer.  He has more than 25 years of experience in the biotech and pharmaceutical industry, including senior executive leadership roles in global marketing, sales, and commercial operations.  Mr. Happel most recently served as Chief Commercial Officer of Allergen Research Corporation, where he led global commercial and corporate development.  Prior to Allergen, Mr. Happel led commercial functions at Dynavax Technologies and Aerovance, Inc.  Previously, Mr. Happel held senior-level leadership positions at Dr. Reddy’s Laboratories, Inc.,  Chiron Corporation, InterMune, Inc. and Parke-Davis/Pfizer, where he led the development and commercialization of several market-leading products, including TOBI® for the cystic fibrosis and Actimmune® for the treatment of multiple orphan diseases.  Mr. Happel received a B.A. in Chemistry from Indiana University and an M.B.A. in Marketing from Indiana State University.

image description

Dr. Polu is our Chief Medical Officer since joining the company in January 2015 and is responsible for global clinical development programs, medical affairs and other related functions. He most recently served as Chief Medical Officer at CytomX Therapeutics, a privately held biotechnology company focused on the development of Probody™ therapeutics, a novel monoclonal antibody platform for the treatment of cancer. Prior to that, he served as Vice President of Clinical Development at Affymax, where he led multiple functions, including clinical sciences, clinical operations and drug safety/pharmacovigilance and was integral to the development and regulatory approval of the company’s first drug, OMONTYS®, a pegylated peptide for the treatment of anemia due to chronic kidney disease. He previously served as Executive Director of Global Development at Amgen where he led late-stage clinical research programs across a wide range of therapeutic areas including nephrology, diabetes and heart failure and executed on several large cardiovascular outcomes trials. He also led the global clinical activities to support commercialization for EPOGEN® and Aranesp®.Dr. Polu received a B.A. from Stanford University and an M.D. from the University of Texas, San Antonio. He completed an internal medicine internship and residency at the University of Colorado as well as clinical and research fellowships in nephrology and transplant at Harvard Medical School in a joint program with Brigham and Women’s Hospital and Massachusetts General Hospital.

image description

Mr. Smith joined the company in January 2015 as Chief Financial Officer and is responsible for finance, corporate development, corporate strategy and IT. Previously, he served as Chief Financial and Business Advisor at Catalyst Biosciences. Prior to that, he was Vice President of Business Development at iPierian and Chief Financial Officer for Memory Pharmaceuticals, where he oversaw all finance, business development, strategic planning, intellectual property and site operation activities. Prior to that, Mr. Smith was Vice President of Business Development at QLT. Before that, he held several positions of increasing responsibility at Chiron and helped establish Chiron’s TOBI® franchise for cystic fibrosis. Throughout his career, Mr. Smith has managed and led numerous successful financings and corporate and product acquisitions, as well as strategic partnerships. Mr. Smith received a B.S. from the University of Virginia and an M.B.A. from the Haas School of Business at the University of California, Berkeley.

image description

Mr. DesJardin joined Raptor in April 2015 as Senior Vice President of Technical Operations and is responsible for Quality, Manufacturing, Supply Chain and Pharmaceutical development. He brings over 35 years of experience in pharmaceutical development at Jazz Pharmaceuticals, Johnson & Johnson, ALZA Corporation, Marion Merrell Dow and Dow Chemical. Mr. DesJardin previously held the position of Senior Vice President of Manufacturing and Technical Development at Jazz Pharmaceuticals where he was senior management sponsor for a new manufacturing facility in Ireland. In addition, he was responsible for all CMC development and diligence for Jazz’s acquisitions of Orphan Medical Inc., Azur Pharma Ltd, EUSA Pharma, and Gentium SpA which has led to over $1 billion on revenue sales for Jazz. Prior to that, at ALZA he was an Engineering Fellow responsible for several successful approvals of controlled release oral drugs including Ditropan XL. Mr. DesJardin received a B.S. in Chemical Engineering from the University of California at Berkeley and he is a registered Professional Engineer in the State of California.

image description

Ashley C. Gould joined Raptor in July 2015 as Senior Vice President, General Counsel and Corporate Governance. Most recently, she served as Senior Vice President, Governmental Affairs and Chief Legal, Compliance Officer and Secretary at Hyperion Therapeutics. Prior to that, Ms. Gould served as Vice President, Corporate Development and Chief Legal Officer at 23andMe, Inc. a personal genetics company. Previously, Ms. Gould was Vice President, Legal Affairs at CoTherix, Inc., where she worked on the company’s acquisition by Actelion, and was an associate at the law firms of Wilson Sonsini Goodrich & Rosati PC and O’Melveny & Myers LLP. Ms. Gould received a B.S. in Political Economy of Natural Resources from University of California, Berkeley, and a J.D. from the University of San Francisco School of Law.

image description

Mr. Ford is Vice President of Global Human Resources and joined Raptor in July 2014 from Micromet where he served as Vice President of Human Resources and Administration and successfully led the global integration of Micromet’s team following Amgen’s acquisition of the company.  Prior to that, he was Vice President of Global Human Resources for Bayer Pharmaceuticals where he was responsible for human resources strategic support for multiple businesses worldwide. His career as a human resources leader in the biopharmaceutical industry includes his 14-year tenure at Monsanto where he held a range of management positions with increasing levels of responsibility. Mr. Ford received a B.A. in Human Resources from the University of Kansas.

image description

Mr. Bendrick joined the company in March 2015 as Vice President, Intellectual Property Counsel. He has 20 years of experience building and defending the patent portfolios protecting pharmaceutical products. Mr. Bendrick most recently served as Consultant and Vice President, Intellectual Property at InterMune, Inc., where he developed the portfolio of 19 Orange Book listed patents for the pulmonary fibrosis drug ESBRIET. Prior to InterMune, Mr. Bendrick was Director, Intellectual Property at PDL, Inc., where he helped defend PDL’s humanized antibody patents against a record number of Opponents in a European Opposition proceeding. Prior to InterMune, Mr. Bendrick was a Senior Associate at the Menlo Park, CA office of Howrey, LLP and an attorney at the Banner & Witcoff, LLP law firm in Chicago. He received a B.A. in Economics from University of California, Santa Cruz, a J.D. from Arizona State University and an M.S. in Biotechnology from Northwestern University.

image description

Ms. de Craecker is Senior Vice President and General Manager of European Operations since joining Raptor in August 2014 and is responsible for managing European operations and overseeing PROCYSBI’s launch in European markets. She came from Shire where she served as Vice President and General Manager of Europe, Rare Diseases. Prior to that, she helped build the European operations at TKT and led the regional and global strategic and operational marketing efforts for their rare disease operations. Ms. Craecker received a masters degree in Nutrition from the Faculty of Medicine at the University of Leuven.

image description

Dr. Lee joined Raptor in October 2014 as Vice President of Corporate Strategy and Communications. She brings more than 20 years of experience in the healthcare industry, predominantly as a sell-side equity research analyst covering the biotechnology sector. Most recently, Dr. Lee was a managing director and senior research analyst at Janney Montgomery Scott LLC, where she focused on orphan drug, oncology and women’s health companies. Prior to Janney, she held managing director roles and progressively senior research analyst positions at ThinkEquity LLC, Pacific Growth Equities (acquired by Wedbush Securities), Jefferies & Co and Stephens Inc. Dr. Lee received a B.S. in Biological Sciences from Stanford University and a D.O. from Kirksville College of Osteopathic Medicine. She is a licensed physician and member of the American Osteopathic Association as well as author of several papers published in leading scientific and clinical journals.

image description

Mr. Mosbrooker joined Raptor in November 2012 and has served as Senior Vice President of Commercial for the US and Latin America since January 2016. He has over ten years of experience in all aspects of biopharmaceutical commercial operations, covering orphan drugs to blockbusters. Prior to joining Raptor, Mr. Mosbrooker served as Executive Director of Commercial Operations and Market Access at Enobia Pharma, Inc. Previously, he served in various commercial operational capacities at Onyx Pharmaceuticals, Jazz Pharmaceuticals Inc., Chiron Corporation and Millennium Pharmaceuticals. He also has extensive experience in management and technology consulting at IBM, Teltech Resource Network Corporation and Kohler Company. Mr. Mosbrooker received a B.S. in Industrial Engineering from the University of Wisconsin, Madison.

image description

Ms. Murray joined Raptor in March 2015 as Vice President of Global Regulatory Affairs, and is responsible for leading all aspects of global regulatory affairs. She brings more than 20 years of experience from both large pharmaceutical and small biotechnology companies, including Gilead Sciences, Alexza Pharmaceuticals and SmithKline Beecham Pharmaceuticals. Ms. Murray recently served as Vice President of Regulatory Affairs and Quality Assurance at Achaogen, a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel antibacterials to treat multi-drug resistant gram-negative infections. Her early career was spent as clinical biochemist at the Western General Hospital in Edinburgh and Yorkhill Hospital in Glasgow, UK. Ms. Murray received an MS in Clinical Biochemistry from the University of Newcastle-upon-Tyne, UK and a B.S. in Biochemistry from Liverpool University. She is also US RAC certified.

image description

Joel M. Rothman joined the company in June 2015 as Vice President of Development Operations. Joel is a clinical operations leader who brings to Raptor more than 25 years of experience in the pharmaceutical, contract research organization, and biotechnology industries. Prior to joining Raptor, Joel served as Vice President of Development Operations at Jazz Pharmaceuticals where he was responsible for clinical operations, clinical contracts and outsourcing, biostatistics, and data management and was involved in the due diligence and integration of corporate acquisitions. Joel served as Senior Director and General Manager of Early Phase and International Consulting, Director of Strategic Business Development, and Director of Regional Operations at ICON Clinical Research, Inc. Previously, he held positions in clinical research, operations, and development at Anergen, Genentech, and Procter & Gamble Pharmaceuticals. Joel received his BS degree in Biology from Albright College in Reading, Pennsylvania.

image description

Mr. Scott joined Raptor as VP and Corporate Controller in March 2016 bringing over 20 years of experience as a healthcare executive with the abilities to create and implement programs which result in cost savings and profits. Prior to Raptor, he served as CFO for various healthcare organizations including Spectrum Pharmaceuticals, Biolase, North American Scientific, Alsius Corporation and Cardiac Science. Mr. Scott received a B.S. in Business Administration from the University of Southern California and is a Certified Public Accountant (inactive).

image description

Micheline Wille joined Raptor in February 2015 as Vice President, Medical Affairs in Europe. Dr. Wille most recently led the Shire European Medical Affairs team in Switzerland. Prior to that, she held several positions of increasing scope and responsibility in Medical Affairs at AstraZeneca and TiGenix. Dr. Wille received an M.D. from the Catholic University of Leuven, an MBA from the Vlerick Leuven Ghent Management School and a Masters in Hospital Management from the Solvay Business School.

image description

Ms. Yost joined Raptor in January 2016 as Vice President, Pharmacovigilance and Drug Safety. She brings 18 years of experience in the biotech and pharmaceutical industry focused in global pharmacovigilance/drug safety from early drug development through marketing and across diverse therapeutic areas including orphan diseases. Prior to joining Raptor, she served as Senior Director, Head of Pharmacovigilance, at Xenoport where she was responsible for directing the overall PV program for the investigational and commercial portfolio. Previously, Ms. Yost was Director of Medical Evaluation and Risk Management at BioMarin, where she managed and led global signal detection, risk management, aggregate safety reporting activities. Prior to that, she was Associate Director and Safety Management Team lead for the Cardiovascular and CNS therapeutic areas at AstraZeneca and as Scientific Safety Lead for the Rheumatology and Hematology/Oncology portfolio at Wyeth. Ms. Yost received her B.S. and Doctor of Pharmacy degrees from the Philadelphia College of Pharmacy & Science.

image description

Ms. Zdanowicz joined Raptor in March 2016 as Vice President of Quality, bringing more than 25 years of experience in the pharmaceutical and biotechnology industries. Previously, she served as Sr. Director, Corporate Quality at Gilead Sciences where she was responsible for developing the Quality Policies and Strategies, leading development and implementation of the Quality Management System and managing Field Alerts/Recalls. Prior to that, she served as Site Head of Quality at Dendreon and Teva and held positions within Quality Assurance, Validation, Compliance and Quality Control at Allergan, Medeva and Baxter. Ms. Zdanowicz received a  B.S. in Chemistry from University of Southern California and an M.S. in Engineering from University of Michigan.

Mr. Anderson has served as a director of the Company since September 2009 and has more than 30 years of biopharmaceutical/medical technology sector experience, primarily focused in financial management. Mr. Anderson worked at Dow Pharmaceutical Sciences, Inc. (now a wholly owned subsidiary of Valeant Pharmaceuticals International) from July 2003 until he retired in June 2010. He most recently served as Dow’s Managing Director since January 2009 and previously served as Chief Financial Officer and Vice President, Finance and Administration. Prior to joining Dow in 2003, Mr. Anderson was Chief Financial Officer for Transurgical, Inc., a private medical technology company. Prior to that, Mr. Anderson served as Chief Operating Officer and Chief Financial Officer at BioMarin Pharmaceutical Inc. from June 1998 to January 2002. Prior to June 1998, Mr. Anderson held similar executive-level positions with other biopharmaceutical companies, including Syntex Laboratories, Chiron Corporation, Glycomed Incorporated and Fusion Medical Technologies. Mr. Anderson also served as an officer in the United States Army Corps of Engineers, as a strategic planner and operational profit and loss manager at General Electric and as a finance manager at Memorex. Mr. Anderson holds an M.B.A. from Harvard University, an M.S. in Administration from George Washington University and a B.S. in Engineering from the United States Military Academy. We nominated Mr. Anderson to the Board of Directors primarily due to his 30 years of healthcare experience in the areas of operations and finance.

Dr. Bruhn has served as a director of the Company since April 2011. Recently, she served as President and Chief Executive Officer of Promedior, Inc., a privately held, clinical-stage immunotherapy company pioneering the development of targeted therapeutics to treat diseases involving fibrosis. She successfully negotiated an exclusive agreement with BMS for the right to acquire Promedior and gain worldwide rights to the lead asset PRM-151, with a total deal potential of $1.25 billion. Prior to that, she spent 13 years at Shire Human Genetic Therapies (HGT), a division of Shire plc, specializing in the development and commercialization of treatments for orphan diseases, where she held a series of position of increasing responsibility, with her final position as Senior Vice President, Strategic Planning and Program Management. During her tenure at Shire HGT, Dr. Bruhn was responsible for establishing the program management function, driving strategic planning and portfolio management, and for global regulatory affairs. She played a key role in the development, registration and global expansion of Shire HGT’s products REPLAGAL(r), ELAPRASE(r) and VPRIV(r). She also played a key role in Shire HGT’s portfolio expansion through acquisitions, including the acquisition of FIRAZYR(r). Prior to her time at HGT, Dr. Bruhn held various positions at Cytotherapeutics, Inc., a biotechnology company. Dr. Bruhn holds a Ph.D. in Chemistry from Massachusetts Institute of Technology and was a Postdoctoral Fellow in the Department of Human Genetics at Harvard Medical School. We nominated Dr. Bruhn to the Board of Directors due to her extensive healthcare experience in the orphan disease arena.

Dr. Franklin has served as a director of the Company since September 2009. Dr. Franklin has served as the Chief Executive Officer and a director of Tarix Pharmaceuticals, a drug development company, since 2004. He has also served as the Chairman of Pathfinder, LLC, a regenerative medicine company, since 2009. Dr. Franklin served as Chairman of the board of directors of SyntheMed, Inc., a biomaterials company engaged in the development and commercialization of medical devices, from June 2003 to September 2011, and as a director of that company from December 2000 to September 2011. Pathfinder, LLC and SyntheMed, Inc. merged in September 2011, at which point the combined companies were renamed Pathfinder Cell Therapy, Inc., and Dr. Franklin became the Chief Executive Officer and a director of the surviving entity. Dr. Franklin received an M.A. in Mathematics from University of Wisconsin, a Ph.D. in Mathematics from Brandeis University and an M.D. from Boston University School of Medicine. We nominated Dr. Franklin to the Board of Directors due to his experience as a CEO and chairman of various healthcare companies.

Dr. Gemayel began serving on the Board of Raptor in January 2015. He has over 25 years of experience in the pharmaceutical industry, including management and executive positions spanning the U.S., Europe and the Middle East. Since 2010, he has been a consultant for several biotechnology companies and venture capital funds. From 2008 to 2009, Dr. Gemayel was President and CEO of Altus Pharmaceuticals. From 2003 to 2008, he was Executive Vice President at Genzyme Corporation where he was responsible for the company’s worldwide therapeutics businesses, which included lysosomal storage disorders, endocrinology, nephrology, transplant and bio-surgery. From 1998 to 2003, he held progressively senior roles at Hoffmann La-Roche and Roche Labs. Dr. Gemayel completed his doctorate in pharmacy at St. Joseph University in Beirut, Lebanon, and earned a Ph.D. in pharmacology at Paris-Sud University in Paris, France. Dr. Gemayel currently serves on the Board of Directors of Dimension Therapeutics, Momenta Pharmaceuticals and Supernus and is the Chairman of the Boards of OxThera AB, Enterome, and Orphazyme ApS. He has previously served on the Board of Adolor Corporation, Epitherapeutics, NPS Pharmaceuticals, Prosensa and as Chairman of the Boards of FoldRx, Syndexa and Vascular Magnetics.

Dr. Keltner has served on the Board of the Company since September 2009. Dr. Keltner is Chief Executive Officer of EPISTAT, an international healthcare technology transfer, corporate risk management and healthcare strategy company that he founded in 1972. Dr. Keltner also served as the Chief Executive Officer of AgonOx, a biotech company developing OX40 agonists for use in cancer therapy, from 2011 to 2013. From 2010 until 2011, Dr. Keltner was the President of Novici Biotech, a privately held gene and protein optimization firm, and from 2001 to 2010, he was Chief Executive Officer and President of Light Sciences Oncology, a privately held biotechnology company developing a late-stage, light-activated therapy for hepatocellular cancer and other solid tumors. From 1997 to 2004, Dr. Keltner was Chief Executive Officer of Metastat, Inc., a development-stage biotech company focused on cancer metastasis. Dr. Keltner holds positions on the boards of Infostat, BioQuiddity, Oregon Life Sciences and Goodwell Technologies. He previously served as a director of Light Sciences Corporation, Vital Choice, Thesis Technologies, Oread Companies and MannKind Corporation. Dr. Keltner has also been a scientific advisory board member at Lifetime Corporation, ASB Meditest, Oread Laboratories, Hall-Kimbrell and AAIPharma. Dr. Keltner is an Associate Professor at Case Western Reserve School of Medicine and a Guest Lecturer and Director in the Bioethics Program at Columbia University School of Medicine. He is currently a member of the American Society of Clinical Oncology, the American Medical Association, the International Association of Tumor Marker Oncology, the American Association of Clinical Chemistry and the Drug Information Association. Dr. Keltner received an M.S. in Epidemiology and Biostatistics, a Ph.D. in Biomedical Informatics and an M.D. from Case Western Reserve University in Cleveland, Ohio. Dr. Keltner has also authored many research publications.

Mr. Lapointe joined Raptor’s Board in January 2015 with nearly 20 years of experience in the pharmaceutical and medical device industries. He has been Chairman of Raptor’s Board since August 2015. Currently, he is Co-Founder and CEO of Cerium Pharmaceuticals, a biopharmaceutical company focused on developing and commercializing medicines for patients with rare diseases. Previously, he held several managerial and executive roles at Sigma-Tau Pharmaceuticals culminating in serving as CEO from 2008 to 2012. Prior to that, Mr. Lapointe held various financial and operations roles at AstenJohnson, Medical Plastic Devices, Inc. and Ingram & Bell Meditron. Prior to joining Ingram & Bell Meditron, he served as a Senior Manager at Zittrer Siblin Stein Levine, a management consultant mergers and acquisitions firm based in Montreal, Canada. Mr. Lapointe began his career at Price Waterhouse in 1982 as a Chartered Accountant with progressive advancement from staff accountant to Audit Manager. He received a Bachelor of Commerce degree from Concordia University, a Graduate Diploma in Public Accountancy from McGill University and an MBA from Duke University. Mr. Lapointe is a Certified Public Accountant in Illinois. He currently serves as a member of the Board of Directors of SciClone Pharmaceuticals and Soligenix, and on the Board of Trustees of the Keck Graduate Institute of Applied Life Sciences. He has previously served on the Board and as Chair of the Rare Disease Committee of the Pharmaceutical Research and Manufacturers of America (PhRMA) and as a member of the Board of Directors of Questcor Pharmaceuticals.

Julie Anne Smith serves as Raptor’s President and CEO and is a member of the Board of Directors. She joined the company in 2012 as Executive Vice President, Strategy and Chief Operating Officer. Prior to joining Raptor, Ms. Smith was Chief Commercial Officer of Enobia Pharma, Inc., a private, clinical stage orphan company acquired by Alexion (ALXN). Previously, she served as Vice President, Commercial where she managed commercial functions at Jazz Pharmaceuticals and as Vice President, Global Marketing at Genzyme General where she led the worldwide commercialization and planning for Myozyme, an infused enzyme replacement therapy for an ultra-orphan genetic disease. In her nearly 20 years in biotech, Ms. Smith has served in executive management of both private and public biotech firms, mostly in orphan drug development and commercial product opportunities. She holds a B.S. in Biological and Nutritional Science from Cornell University.

Dr. Starr is a co-founder of Raptor and has served as the Chief Executive Officer and director thereof since its inception in 2006. Following his resignation as CEO of Raptor in December 2014, Dr Starr has co-founded and serves as Executive Chairman of Monopar Therapeutics, a private biopharma company focusing on developing potential therapies for ultra-orphan oncology indications. Dr. Starr co-founded BioMarin Pharmaceutical Inc. in 1997 where he last served as Senior Vice President and Chief Scientific Officer prior to leaving to start Raptor in 2006. As Senior Vice President at BioMarin, Dr. Starr was responsible for managing a Scientific Operations team of 181 research, process development, manufacturing and quality personnel through the successful development of commercial manufacturing processes for its enzyme replacement products, and supervised the cGMP design, construction and licensing of BioMarin’s proprietary biological manufacturing facility. From 1991 to 1998, Dr. Starr supervised research and commercial programs at BioMarin’s predecessor company, Glyko, Inc., where he served as Vice President of Research and Development. Prior to his tenure at Glyko, Inc., Dr. Starr was a National Research Council Associate at the National Institutes of Health. Dr. Starr earned a B.S. from Syracuse University and a Ph.D. in Biochemistry and Molecular Biology from the State University of New York Health Science Center, in Syracuse, New York. We nominated Dr. Starr to the Board of Directors due to his extensive experience at BioMarin Pharmaceutical.

Board Committee Compositions

Audit Committee

Chair:

Raymond W. (“Bill”) Anderson

Members:

Richard L. Franklin M.D., Ph.D.

Gregg Lapointe


Nominating and Governance Committee

Chair:

Richard L. Franklin M.D., Ph.D.

Members:

Suzanne L. Bruhn Ph.D.

Georges Gemayel, Ph.D.

Llew Keltner M.D., Ph.D.


Compensation Committee

Chair: 

Suzanne L. Bruhn Ph.D.

Members:

Raymond W. (“Bill”) Anderson

Georges Gemayel, Ph.D.

Llew Keltner M.D., Ph.D.


Pipeline Steering Committee

Chair: 

Georges Gemayel, Ph.D.

Members:

Suzanne Bruhn, Ph.D.

Llew Keltner, M.D., Ph.D.

Rick Franklin, M.D., Ph.D.